Electroconvulsive Treatment for Depression Alters Mitochondrial Serum MetabolitesVise andre og tillknytning
2026 (engelsk)Inngår i: Biological Psychiatry: Global Open Science, E-ISSN 2667-1743, Vol. 6, nr 5, artikkel-id 100754Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]
BACKGROUND: Electroconvulsive therapy (ECT) is the most effective treatment for severe and treatment-resistant depression, but its biological mechanisms remain poorly understood. Given the pivotal role of mitochondria in cellular energy metabolism and their proposed involvement in the pathology of depression, we aimed to investigate whether ECT alters mitochondrial metabolism.
METHODS: We included 102 patients with major depressive disorder referred for ECT at 7 Swedish hospitals. Fasting serum samples were collected at 3 time points: immediately before the first ECT session (T0), 30 minutes after the first session (T1), and before the sixth session (T2). Proton nuclear magnetic resonance spectroscopy was used to quantify metabolites related to the tricarboxylic acid cycle and amino acid metabolism.
RESULTS: Acutely (T0→T1), serum levels of citrate, glucose, glutamine, and pyruvate increased significantly, while formate and phenylalanine decreased. Across the treatment course (T0→T2), alanine and pyruvate levels increased, whereas the ketone bodies acetoacetate, acetone, and 3-hydroxybutyrate decreased significantly. An exploratory analysis indicated that the reduction in ketone bodies (T0→T2) was confined to patients showing clinical improvement, as defined by the Clinical Global Impressions-Improvement scale.
CONCLUSIONS: ECT induces both acute and sustained alterations in mitochondrial energy metabolism. These findings suggest that ECT modulates systemic mitochondrial function, warranting further investigation into how these metabolic changes relate to clinical improvement.
sted, utgiver, år, opplag, sider
Elsevier, 2026. Vol. 6, nr 5, artikkel-id 100754
Emneord [en]
Clinical study, Electroconvulsive treatment, Energy metabolism, Major depression, Metabolomics
HSV kategori
Identifikatorer
URN: urn:nbn:se:oru:diva-129670DOI: 10.1016/j.bpsgos.2026.100754ISI: 001803160800001PubMedID: 42339150OAI: oai:DiVA.org:oru-129670DiVA, id: diva2:2081298
Forskningsfinansiär
Swedish Research Council, 2022-01643Swedish Foundation for Strategic Research, KF10-0039The Swedish Brain Foundation, FO2025-0004-HK-212
Merknad
Funding Agencies:
This work was supported by grants from the Swedish Research Council (Grant No. 2022-01643 [to ML]), the Swedish Foundation for Strategic Research (Grant No. KF10-0039 [to ML]), Hjärnfonden/the Swedish Brain Foundation (Grant No. FO2025-0004-HK-212 [to ML]), and the Swedish Government under the LUA/ALF agreement (Grant No. ALFGBG-1005343 [to ML]).
2026-06-292026-06-292026-07-24bibliografisk kontrollert